New study demonstrates that Baclofen helps patients with severe alcohol dependence maintain abstinence
April 23, 2015, Austria, Vienna: Results revealed today at The International Liver Congress™ 2015, show that in patients with alcohol-induced liver disease (ALD), Baclofen has a positive impact on alcohol consumption and overall measures of liver function and harm.
ALD is a major cause of alcohol-related mortality and helping patients with ALD to stop drinking is a primary goal of treatment. The primary aim of this study was to measure the effectiveness and tolerability of Baclofen in maintaining abstinence in this difficult to treat group, and to determine if this resulted in a reduction in standard measures of liver damage.
The results show promising outcomes for these patients, helping them to reduce their alcohol consumption as well as improving overall indicators of liver function and lowering physical dependence. A randomised controlled trial is now needed to confirm the benefit of Baclofen in this patient group.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.
About EASL (www.easl.eu)
Since EASL’s foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
For more information, please contact the ILC Press Office at:
• firstname.lastname@example.org or
• +44 (0)20 3580 5444